35 U.S.C. 271
Also called Section 271, 35 USC 271
35 U.S.C. 271 is the US statute under which, except as otherwise provided in Title 35, making, using, offering to sell, or selling a patented invention within the United States, or importing it into the United States, without authority during the patent term constitutes Patent infringement1.
Direct and indirect infringement
| Subsection | What it provides |
|---|---|
| 271(a) | Except as otherwise provided in Title 35, a person infringes by making, using, offering to sell, or selling a patented invention within the United States, or importing it into the United States, without authority during the term of the patent1. |
| 271(b) | A person who actively induces infringement of a patent is liable as an infringer1. |
| 271(c) | A person is liable for Contributory infringement if they offer to sell or sell within the United States, or import into the United States, a component of a patented machine, manufacture, combination, or composition, or a material or apparatus for use in practicing a patented process, that is a material part of the invention, knowing it is especially made or adapted for use in infringing the patent and where it is other than a staple article or commodity of commerce suitable for substantial noninfringing use1. The US Supreme Court held in Aro Manufacturing v. Convertible Top Replacement (1961) that contributory infringement requires direct infringement2. |
Relief, regulatory activity, and cross-border conduct
| Subsection | What it provides |
|---|---|
| 271(d) | An owner otherwise entitled to relief for infringement or contributory infringement cannot be denied relief or found to have misused or illegally extended the patent right on these grounds alone: earning revenue from acts that would constitute contributory infringement if performed by another without consent, licensing or authorizing another to perform acts that would constitute contributory infringement without consent, seeking to enforce the patent against infringement or contributory infringement, or refusing to license or use rights to the patent1. The same protection applies when the owner conditions a license of patent rights or the sale of a patented product on taking a license to another patent or buying a separate product, unless, in view of the circumstances, the owner has market power in the relevant market for the conditioning patent or patented product1. |
| 271(e) | Under section 271(e)(1), specified acts in or into the United States are not infringement if done solely for uses reasonably related to developing and submitting information under a federal law regulating the manufacture, use, or sale of drugs or veterinary biological products1. This exemption excludes the specified new animal drugs and veterinary biological products made primarily by certain genetic-manipulation technologies1. See Bolar exemption1. Section 271(e)(2) treats certain drug, veterinary biological product, and biological product approval applications as acts of infringement when the statutory conditions are met1. Section 271(e)(5) separately addresses declaratory-judgment jurisdiction in cases involving specified applications with a Paragraph IV certification, subject to the conditions in that paragraph1. |
| 271(f) | Section 271(f)(1) covers unauthorized supply, or causing supply, in or from the United States of all or a substantial portion of the components of a patented invention, uncombined in whole or in part, in a manner that actively induces their combination abroad1. Section 271(f)(2) covers unauthorized supply, or causing supply, in or from the United States of an uncombined or partly uncombined component that is especially made or adapted for the patented invention and is not a staple article or commodity of commerce suitable for substantial noninfringing use1. The supplier must know of the special manufacture or adaptation and intend combination abroad1. Under either paragraph, the combination would have to infringe if it took place in the United States1. |
| 271(g) | Among other conditions, a person is liable under subsection (g) for importing into the United States or offering to sell, selling, or using within the United States, without authority and during the term of the US process patent, a product made by the patented process, subject to the subsection's rules on remedies for noncommercial use or retail sales and on material changes by later processes or incorporation as a trivial and nonessential component1. |
Definitions within section 271
| Subsection | What it provides |
|---|---|
| 271(h) | The text of section 271(h) defines ‘whoever’ to include a state, a state instrumentality, and an officer or employee of either acting in an official capacity1. Its text subjects those persons and entities to Title 35 on the same terms as a nongovernmental entity1. |
| 271(i) | For section 271, an offer for sale or offer to sell by someone other than the patentee or a designee must contemplate a sale before the patent expires1. |
The Patent Remedy Act added section 271(h), which expanded the definition of ‘whoever,’ and section 296, which expressly addressed state sovereign immunity from federal patent suits1,3. In Florida Prepaid v. College Savings Bank (1999), the US Supreme Court held that Congress could not validly abrogate that immunity through the Patent Remedy Act under section 5 of the Fourteenth Amendment3.
How the Supreme Court applies subsection (b)
In Global-Tech Appliances v. SEB (2011), the US Supreme Court held that induced infringement under subsection (b) requires the defendant to know that the induced acts constitute patent infringement4.
The US Supreme Court in Global-Tech (2011) held that willful blindness can satisfy that knowledge requirement when the defendant subjectively believes there is a high probability that a fact exists and takes deliberate actions to avoid learning of that fact4.
In Limelight Networks v. Akamai Technologies (2014), the US Supreme Court held that subsection (b) imposes no inducement liability where direct infringement has not occurred under subsection (a) or any other statutory provision, a distinction relevant to Divided infringement5.
Questions people ask
Check a product
FTO Search AI Agent
Turn product details into a reviewable search strategy, focused patent candidates, and evidence your IP team can take further.
Run FTO SearchCan an offer to sell infringe under section 271(a)?
Yes, subject to the other provisions of Title 35, an unauthorized offer during the patent term to sell a patented invention in the United States can infringe1. Section 271(i) requires an offer by someone other than the patentee or a designee to contemplate a sale before expiry1. The Federal Circuit in Transocean Offshore Deepwater Drilling v. Maersk (2010) explained that the offer need not be accepted and that the territorial inquiry focuses on the contemplated sale6.
Can an approval submission itself be an act of infringement?
Yes. Section 271(e)(2) treats specified submissions as infringement when the purpose is to obtain approval to commercially make, use, or sell the product before the relevant patent expires, and that patent claims the product or its use1. Subparagraphs (A) and (B) identify the relevant drug and veterinary filings1. For a biological-product application, subparagraph (C)(i) concerns a patent identified on the list described in Public Health Service Act section 351(l)(3), including additions under section 351(l)(7)1. If the applicant fails to provide the application and information required by section 351(l)(2)(A), subparagraph (C)(ii) instead addresses a patent that could be identified under section 351(l)(3)(A)(i)1.
Can inducement exist without direct infringement?
No, the US Supreme Court held in Limelight Networks v. Akamai Technologies (2014) that inducement under subsection (b) requires direct infringement under subsection (a) or another statutory provision5.
How it connects
Go from the term to the task
Read how the method works, run it on your own product or idea, then try a free tool.
- 01 / How-toHow to run a freedom-to-operate analysisScope, search, claim review and the report counsel will ask for.Read
- 02 / AI agentFTO Search AI AgentTurn product details into a reviewable search strategy, focused patent candidates, and evidence your IP team can take further.Run it
- 03 / Free toolAI prior art searchDescribe an idea, get the closest patents.Try tool